Metabolomics

Dataset Information

0

Health outcomes of fruit juice and fruity beverage: a comparative analysis of gut microbiota and metabolomics in rats (Metabolomics assay)


ABSTRACT:

BACKGROUND: Evidence on the relationship between food processing and health outcomes has been increasing steadily. Under this context, ultra-processing food, such as sugar-sweetened fruity beverages (SS-FB), is associated with a higher risk of metabolic syndrome. However, whether drinking fruit juice not from concentrate (NFC-FJ), which belongs to minimally processed food, causes poor health or not is controversial. The major goal was to determine the impact of fruit drinks with different processing degrees on health via the interaction of gut microbiota and metabolomics.

RESULTS: Significant different trends in metabolic syndrome were found between NFC-FJ and SS-FB in a 4-week experiment. NFC-FJ increased alpha diversity and decreased F/B ratio compared to SS-FB. The modulated bacterial taxa by NFC-FJ increased lipid metabolism as well as decreased insulin resistance and inhibited the dimethyl-L-arginine (ADMA) formation from S-adenosyl-L-methionine (SAM), contributing to a lower risk of metabolic syndrome in rats. However, SS-FB led to a higher risk of metabolic syndrome in rats with increased food intake and weight change. Additionally, SS-FB with the fructose-to-glucose ratio of 1.5 corresponded to an increase in kidney mass and serum C17-sphinganine level, boosting risks for kidney disease. More than 10 times higher flavonoid content in NFC-FJ than SS-FB was caused by processing degrees, which might be partly responsible for the alteration of gut microbiota.

CONCLUSIONS: Our results revealed that rich flavonoids in minimally processed fruit juice decreased the risk of metabolic syndrome in rats through the pathway of insulin resistance via gut microbiota alteration, while ultra-processed fruit beverages enhanced the risk of metabolic syndrome. Based on our data, NFC fruit juice should be considered a healthy choice.


Metabolomics assay is reported in the current study MTBLS3943.

Lipidomics assay is reported in MTBLS4108.

INSTRUMENT(S): Liquid Chromatography MS - positive - reverse phase

SUBMITTER: Kewen Wang 

PROVIDER: MTBLS3943 | MetaboLights | 2022-08-24

REPOSITORIES: MetaboLights

Similar Datasets

2022-08-24 | MTBLS4108 | MetaboLights
2022-05-24 | GSE133686 | GEO
2014-01-01 | E-GEOD-50384 | biostudies-arrayexpress
2016-09-29 | GSE87454 | GEO
2023-09-18 | GSE243459 | GEO
| PRJNA41273 | ENA
2023-03-11 | PXD039605 | Pride
2009-08-09 | E-GEOD-13619 | biostudies-arrayexpress
| 2264615 | ecrin-mdr-crc
2020-12-18 | GSE142261 | GEO